MycoTact®
Accelerating Tuberculosis Detection
Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide, with over 10 million new cases and 1.5 million deaths annually.
The TB diagnostics market is valued at over $2.5 billion, with growing demand for rapid, accessible testing in both high- and low-resource settings.
New TB cases
0M
Million per year (WHO)
Current TB diagnostic Challenges
- Slow Turnaround: Growth culture methods take weeks, delaying urgent care and enabling transmission
- High-cost, Complex Diagnostics: NAAT-based tests require complex readers
- Shortage of Skilled Staff: Sputum microscopy requires specialized equipment and trained personnel
- Inability to detect viable Infection: NAAT tests can’t distinguish between live and dead bacilli
- Drug Resistance: MDR-TB and XDR-TB are on the rise, increasing the need for faster and reliable diagnostics
Without accessible, rapid diagnostic tools, TB continues to spread unchecked, with severe global health and economic consequences.
Our Solution
MycoTact©
Accelerating TB Detection
MycoTact® is a fast, user-friendly test that directly detects viable Mycobacterium tuberculosis within minutes. Unlike current tests, MycoTact® provides real-time, point-of-care TB testing
How MycoTact® works
Collect
No Sample Prep
Directly transfer sample to the VIPER® assay tube containing the MycoTact® assay
Read
Reader Agnostic
Place the VIPER® assay tube containing the sample, into the DeNIRO® mini Fluorometer (point-of-care) or plate reader (lab-based testing)
Treat
Actionable Results
MycoTact® provides actionable data within minutes enabling health care professionals to start immediate targeted treatment
Benefits to healthcare providers
Supports Early Intervention
Enables prompt treatment to reduce transmission and complications
Fast Detection
Identifies TB infections in minutes, not days
Cost Effective
Reduces reliance on costly lab infrastructure and specialized technicians
Accessible Testing
Suitable for out-patient clinics, hospitals, and remote settings
Breakthrough Technology – Our VIPER® platform detects ACTIVE infections with accuracy and speed.
MycoTact® is currently for research use only and is not for use in diagnostic procedures; the performance characteristics of this product have yet to be established